0001415889-24-016939.txt : 20240614
0001415889-24-016939.hdr.sgml : 20240614
20240614163101
ACCESSION NUMBER: 0001415889-24-016939
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240612
FILED AS OF DATE: 20240614
DATE AS OF CHANGE: 20240614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heery Christopher
CENTRAL INDEX KEY: 0001789632
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41259
FILM NUMBER: 241045357
MAIL ADDRESS:
STREET 1: C/O PRECISION BIOSCIENCES, INC.
STREET 2: 302 E. PETTIGREW STREET, SUITE A-100
CITY: DURHAM
STATE: NC
ZIP: 27701
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcellx, Inc.
CENTRAL INDEX KEY: 0001786205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 472855917
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 BRIDGE PARKWAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 240-327-0603
MAIL ADDRESS:
STREET 1: 800 BRIDGE PARKWAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
4
1
form4-06142024_080657.xml
X0508
4
2024-06-12
0001786205
Arcellx, Inc.
ACLX
0001789632
Heery Christopher
C/O ARCELLX, INC.
800 BRIDGE PARKWAY
REDWOOD CITY
CA
94065
false
true
false
false
CHIEF MEDICAL OFFICER
1
Common Stock
2024-06-12
4
M
0
7964
6.28
A
17242
D
Common Stock
2024-06-12
4
M
0
12036
15
A
29278
D
Common Stock
2024-06-12
4
S
0
19918
55.1297
D
9360
D
Common Stock
2024-06-12
4
S
0
82
56.0334
D
9278
D
Stock Option (right to buy)
6.28
2024-06-12
4
M
0
7964
0
D
2031-06-09
Common Stock
7964
87209
D
Stock Option (right to buy)
15
2024-06-12
4
M
0
12036
0
D
2032-02-03
Common Stock
12036
203169
D
Includes 340 shares acquired under the Issuer's 2022 Employee Stock Purchase Plan on May 14, 2024.
The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 22, 2023.
Represents the weighted average share price of an aggregate total of 19,918 shares sold in the price range of $55.00 to $55.96 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average share price of an aggregate total of 82 shares sold in the price range of $56.02 to $56.04 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021.
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022.
/s/ Michelle Gilson, as Attorney-in-Fact
2024-06-14